These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 37383719)

  • 1. Application of natural polysaccharides and their novel dosage forms in gynecological cancers: therapeutic implications from the diversity potential of natural compounds.
    Li Y; Zhang C; Feng L; Shen Q; Liu F; Jiang X; Pang B
    Front Pharmacol; 2023; 14():1195104. PubMed ID: 37383719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune checkpoint blockades in gynecological cancers: A review of clinical trials.
    Peng H; He X; Wang Q
    Acta Obstet Gynecol Scand; 2022 Sep; 101(9):941-951. PubMed ID: 35751489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical analysis of 23 cases with simultaneous double primary gynecological malignant tumors].
    He Y; Wang Y; Ji C; Liu Y; Wu YM
    Zhonghua Fu Chan Ke Za Zhi; 2022 May; 57(5):352-360. PubMed ID: 35658326
    [No Abstract]   [Full Text] [Related]  

  • 4. Role of CC-chemokine ligand 2 in gynecological cancer.
    Zhang JJ; Liu W; Xing GZ; Xiang L; Zheng WM; Ma ZL
    Cancer Cell Int; 2022 Nov; 22(1):361. PubMed ID: 36403055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A bioinformatics analysis of the clinicopathological and prognostic significance of
    Zheng HC; Ren DH; Zhang CY; Chen Y; Zhang L
    J Obstet Gynaecol; 2023 Dec; 43(1):2216280. PubMed ID: 37227120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Research progress on the application of organoids in gynecological tumors.
    Shen Y; Wang Y; Wang SY; Li C; Han FJ
    Front Pharmacol; 2024; 15():1417576. PubMed ID: 38989138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of Immune Checkpoint Inhibitors in Gynecological Cancers: What Do Gynecologists Need to Know before Using Immune Checkpoint Inhibitors?
    Lee SM; Lee S; Cho HW; Min KJ; Hong JH; Song JY; Lee JK; Lee NW
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive analysis of the prognostic value and immune function of the
    Zhou Q; Cao FH; Liu H; Zuo MZ
    Am J Transl Res; 2021; 13(4):2041-2059. PubMed ID: 34017374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of Extracellular Vesicles in Gynecologic Cancer Treatment.
    Zhang R; Zou Y; Luo J
    Bioengineering (Basel); 2022 Nov; 9(12):. PubMed ID: 36550946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of the RNA-binding protein family in gynecologic cancers.
    Hao L; Zhang J; Liu Z; Zhang Z; Mao T; Guo J
    Am J Cancer Res; 2023; 13(8):3799-3821. PubMed ID: 37693158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Challenges associated with the management of gynecological cancers in a tertiary hospital in South East Nigeria.
    Iyoke CA; Ugwu GO; Ezugwu EC; Ezugwu FO; Lawani OL; Onyebuchi AK
    Int J Womens Health; 2014; 6():123-30. PubMed ID: 24493933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resveratrol in the Treatment of Gynecological Cancer: Mechanisms and Therapeutic Potential.
    Mozafaryan MJ; Rezaei P; Masoudpoor F; Bahri A; Samini M; Farkhondeh T; Pourhanifeh MH; Samarghandian S
    Curr Med Chem; 2024 May; ():. PubMed ID: 38706364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing the quality of patient-reported outcome measurements for gynecological cancers: a systematic review.
    Moss CL; Guerrero-Urbano T; White I; Taylor B; Kristeleit R; Montes A; Fox L; Beyer K; Sztankay M; Ratti MM; Sisca ES; Derevianko A; MacLennan S; Wood N; Wintner LM; Van Hemelrijck M
    Future Oncol; 2023 Mar; 19(9):663-678. PubMed ID: 37128990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural products' antiangiogenic roles in gynecological cancer.
    Jia S; Li L; Yu C; Peng F
    Front Pharmacol; 2024; 15():1353056. PubMed ID: 38751791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mortality trends and disease burdens of cervical, endometrial and ovarian cancers from 1981 to 2020 in Taiwan.
    Su SY
    Prev Med; 2023 Jul; 172():107551. PubMed ID: 37211252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune Environment and Immunotherapy in Endometrial Carcinoma and Cervical Tumors.
    Lainé A; Gonzalez-Lopez AM; Hasan U; Ohkuma R; Ray-Coquard I
    Cancers (Basel); 2023 Mar; 15(7):. PubMed ID: 37046702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unraveling role of ubiquitination in drug resistance of gynecological cancer.
    Yu L; Chen Z; Wu Y; Xu M; Zhong D; Xu H; Zhu W
    Am J Cancer Res; 2024; 14(5):2523-2537. PubMed ID: 38859858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The bioinformatics analysis of the clinicopathological and prognostic significances of REG4 mRNA in gynecological cancers.
    Zhang CY; Zhang L; Wang ZM; Ren DH; Zheng HC
    J Obstet Gynaecol; 2023 Dec; 43(1):2213764. PubMed ID: 37218920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic potential of Curcuma oil and its terpenoids in gynecological cancers.
    Zhang Y; Peng F; Yu C
    Biomed Pharmacother; 2023 Jan; 157():114016. PubMed ID: 36395609
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.